Organ microenvironment affects growth and metastasis of hepatocellular carcinoma via the TGF-β/Smad pathway in mice

Li,Guocai; Qin,Lunxiu; Ye,Qinghai; Dong,Qiongzhu; Ren,Ning; Jia,Huliang

doi:10.3892/etm.2012.752

Organ microenvironment affects growth and metastasis of hepatocellular carcinoma via the TGF-β/Smad pathway in mice

Authors:
- Guocai Li
- Lunxiu Qin
- Qinghai Ye
- Qiongzhu Dong
- Ning Ren
- Huliang Jia
View Affiliations

Affiliations: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: October 18, 2012 https://doi.org/10.3892/etm.2012.752
Pages: 133-137

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The interaction between cancer and the organ microenvironment is complex, and the transforming growth factor-β (TGF-β)/Smad pathway plays an important role in this interaction. However, the role of the organ microenvironment in hepatocellular carcinoma (HCC) is not well understood. To evaluate the effect of the organ microenvironment and the role of the TGF-β/Smad pathway, MHCC97-H cells were inoculated subcutaneously into nude mice and the resulting MHCC97-H subcutaneous tumor tissues were implanted into the livers of the mice. We found a higher tumor weight and less pulmonary metastasis for the cancers in liver sites than for those in subcutaneous sites; the TGF-β1 levels were significantly different between the tumor models and correlated with tumor metastasis. Our results suggest that the organ microenvironment affects the growth and invasion of liver cancer cells. The TGF-β/Smad pathway is significant in the interaction between HCC and its microenvironment and affects the progression of HCC.

View Figures

View References

1	Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
2	Kurokawa Y, Matoba R, Takemasa I, et al: Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 41:284–291. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lai EC, Fan ST, Lo CM, Chu KM, Liu CL and Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients Ann Surg. 221:291–298. 1995.PubMed/NCBI
4	Ono T, Yamanoi A, Nazmy El Assal O, Kohno H and Nagasue N: Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer. 91:2378–2385. 2001. View Article : Google Scholar
5	Genda T, Sakamoto M, Ichida T, Asakura H, Kojiro M, Narumiya S and Hirohashi S: Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology. 30:1027–1036. 1999. View Article : Google Scholar
6	Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 9:416–423. 2003. View Article : Google Scholar
7	Qin LX and Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 130:497–513. 2004.PubMed/NCBI
8	Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation. 70:498–505. 2002. View Article : Google Scholar : PubMed/NCBI
9	Fidler IJ, Kim SJ and Langley RR: The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem. 101:927–936. 2007. View Article : Google Scholar : PubMed/NCBI
10	Leek RD, Harris AL and Lewis CE: Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol. 56:423–435. 1994.PubMed/NCBI
11	Giannelli G, Fransvea E, Marinosci F, et al: Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol. 161:183–193. 2002. View Article : Google Scholar : PubMed/NCBI
12	Iyer S, Wang ZG, Akhtari M, Zhao W and Seth P: Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther. 4:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
13	Oft M, Peli J, Rudaz C, Schwarz H, Beug H and Reichmann E: TGFbeta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10:2462–2477. 1996. View Article : Google Scholar : PubMed/NCBI
14	Stover DG, Bierie B and Moses HL: A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem. 101:851–861. 2007. View Article : Google Scholar : PubMed/NCBI
15	Song BC, Chung YH, Kim JA, et al: Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer. 94:175–180. 2002. View Article : Google Scholar : PubMed/NCBI
16	Katabami K, Mizuno H, Sano R, et al: Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region. Clin Exp Metastasis. 22:539–548. 2005. View Article : Google Scholar
17	Lin JK and Chou CK: In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor beta 1. Cancer Res. 52:385–388. 1992.PubMed/NCBI
18	Li Y, Tang Y, Ye L, et al: Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 129:43–51. 2003.
19	Li Y, Tang ZY, Ye SL, et al: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 7:630–636. 2001.PubMed/NCBI
20	Zhou J, Tang ZY, Fan J, et al: Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. Clin Cancer Res. 9:6030–6037. 2003.
21	Paget S: The distribution of secondary growths in cancer of the breast. 1889 Cancer Metastasis Rev. 8:98–101. 1989.PubMed/NCBI
22	Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR and Fidler IJ: Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol. 145:365–374. 1994.PubMed/NCBI
23	Takahashi Y, Mai M, Wilson MR, Kitadai Y, Bucana C and Ellis L: Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma. Int J Oncol. 8:701–705. 1996.PubMed/NCBI
24	Welm AL: TGFbeta primes breast tumor cells for metastasis. Cell. 133:27–28. 2008. View Article : Google Scholar
25	Itoh S, Itoh F, Goumans MJ and Ten Dijke P: Signaling of transforming growth factor-b family members through Smad proteins. Eur J Biochem. 267:6954–6967. 2000. View Article : Google Scholar : PubMed/NCBI
26	Kwak HJ, Park MJ, Cho H, et al: Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol Cancer Res. 4:209–220. 2006. View Article : Google Scholar
27	Watanabe H, de Caestecker MP and Yamada Y: Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem. 276:14466–14473. 2001.
28	Kaplan RN, Riba RD, Zacharoulis S, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar
29	Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM and Pienta KJ: The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin. 57:225–241. 2007. View Article : Google Scholar : PubMed/NCBI